Compare stocks

HSIC vs VTVT

Henry Schein Inc and vTv Therapeutics Inc. Class A Common Stock

Compare the businesses

Henry Schein Inc

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The company offers dental merchandise, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, and PPE products; dental equipment, such as dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair; and branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and vitamins. It also provides financial services on a nonrecourse basis, education services for practitioners, consulting, and other services; and consumable merchandise under its own brand. In addition, the company manufactures, markets, and sells dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Further, it is involved in the development and distribution of practice management software, e-services, and other products to health care providers. The company serves customers in dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Open HSIC dashboard ↗

vTv Therapeutics Inc. Class A Common Stock

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.

Open VTVT dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗